日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Patient-derived xenograft models of Fanconi anemia-associated head and neck cancer identify personalized therapeutic strategies

利用范可尼贫血相关头颈癌的患者来源异种移植模型,可以确定个体化的治疗策略。

Grandis, Jennifer R; Li, Hua; Harrison, Benjamin A; Webster, Andrew Lh; Pucilowska, Joanna; Nguyen, Austin; Lee, Jinho; Mills, Gordon B; Gencel-Augusto, Jovanka; Zeng, Yan; Long, Steven R; Kim, Mi-Ok; Lee, Rex H; Kutler, David I; Scognamiglio, Theresa; Brandwein-Weber, Margaret; Urken, Mark; Khodos, Inna; de Stanchina, Elisa; Lin, Yu-Chien; Donovan, Frank X; Chandrasekharappa, Settara C; Jung, Moonjung; Sanders, Mathijs A; Smogorzewska, Agata; Johnson, Daniel E

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236

RRAS 和 RRAS2 突变是肺癌中常见的致癌驱动因素,并且对泛 RAS 抑制剂 RMC-6236 敏感。

Pfeil, Alexander J; Zhang, Tom; Cheng, Ryan; Mattar, Marissa S; Gomez Marti, Juan Luis; Gili, Leo; Lai, Rachel; Khodos, Inna; Master, Rohan P; Dix, Jenna-Marie; Gazzo, Andrea; Arbour, Kathryn C; de Stanchina, Elisa; Febres-Aldana, Christopher A; Ladanyi, Marc; Yang, Soo-Ryum; Somwar, Romel

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236

RRAS 和 RRAS2 突变是肺癌中常见的致癌驱动因素,并且对泛 RAS 抑制剂 RMC-6236 敏感。

Pfeil, Alexander J; Zhang, Tom; Cheng, Ryan; Mattar, Marissa S; Gomez Marti, Juan Luis; Gili, Leo; Lai, Rachel; Khodos, Inna; Master, Rohan P; Dix, Jenna-Marie; Gazzo, Andrea; Arbour, Kathryn C; de Stanchina, Elisa; Febres-Aldana, Christopher A; Ladanyi, Marc; Yang, Soo-Ryum; Somwar, Romel

HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor

HER2抗体-药物偶联物对促纤维增生性小圆细胞肿瘤有效

Zhang, Tom; Febres-Aldana, Christopher A; Liu, Zebing; Dix, Jenna-Marie; Cheng, Ryan; Dematteo, Raymond G; Lui, Allan J W; Khodos, Inna; Gili, Leo; Mattar, Marissa S; Lisanti, Jeanine; Kwong, Charlene; Linkov, Irina; Tipping, Murray J; de Stanchina, Elisa; Odintsov, Igor; Ladanyi, Marc; Somwar, Romel

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

作者更正:Vepafestinib 是一种药理学上先进的 RET 选择性抑制剂,具有高中枢神经系统穿透性和对 RET 溶剂前沿突变的抑制活性。

Miyazaki, Isao; Odintsov, Igor; Ishida, Keiji; Lui, Allan J W; Kato, Masanori; Suzuki, Tatsuya; Zhang, Tom; Wakayama, Kentaro; Kurth, Renate I; Cheng, Ryan; Fujita, Hidenori; Delasos, Lukas; Vojnic, Morana; Khodos, Inna; Yamada, Yukari; Ishizawa, Kota; Mattar, Marissa S; Funabashi, Kaoru; Chang, Qing; Ohkubo, Shuichi; Yano, Wakako; Terada, Ryuichiro; Giuliano, Claudio; Lu, Yue Christine; Bonifacio, Annalisa; Kunte, Siddharth; Davare, Monika A; Cheng, Emily H; de Stanchina, Elisa; Lovati, Emanuela; Iwasawa, Yoshikazu; Ladanyi, Marc; Somwar, Romel

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Zenocutuzumab 是一种 HER2xHER3 双特异性抗体,可有效治疗由 NRG1 基因重排驱动的肿瘤

Schram Alison M, Odintsov Igor, Espinosa-Cotton Madelyn, Khodos Inna, Sisso Whitney J, Mattar Marissa S, Lui Allan J W, Vojnic Morana, Shameem Sara H, Chauhan Thrusha, Torrisi Jean, Ford Jim, O'Connor Marie N, Geuijen Cecile A W, Schackmann Ron C J, Lammerts van Bueren Jeroen J, Wasserman Ernesto, de Stanchina Elisa, O'Reilly Eileen M, Ladanyi Marc, Drilon Alexander, Somwar Romel

Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance

尤文氏肉瘤的前瞻性临床基因组分析:ERF 和 FGFR1 突变作为潜在的生物学和治疗相关性的复发性继发性改变

Ogura, Koichi; Elkrief, Arielle; Bowman, Anita S; Koche, Richard P; de Stanchina, Elisa; Benayed, Ryma; Mauguen, Audrey; Mattar, Marissa S; Khodos, Inna; Meyers, Paul A; Healey, John H; Tap, William D; Hameed, Meera; Zehir, Ahmet; Shukla, Neerav; Sawyers, Charles; Bose, Rohit; Slotkin, Emily; Ladanyi, Marc

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer

MYC促进ROS1融合阳性肺癌对酪氨酸激酶抑制剂的耐药性

Iyer, Sudarshan R; Odintsov, Igor; Schoenfeld, Adam J; Siau, Evan; Mattar, Marissa S; de Stanchina, Elisa; Khodos, Inna; Drilon, Alexander; Riely, Gregory J; Ladanyi, Marc; Somwar, Romel; Davare, Monika A

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.

新型临床前患者来源肺癌模型揭示抑制 HER3 和 MTOR 信号传导是 NRG1 融合阳性癌症的治疗策略

Odintsov Igor, Mattar Marissa S, Lui Allan J W, Offin Michael, Kurzatkowski Christopher, Delasos Lukas, Khodos Inna, Asher Marina, Daly Robert M, Rekhtman Natasha, de Stanchina Elisa, Ganji Gopinath, Ladanyi Marc, Somwar Romel

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

抗HER3单克隆抗体Seribantumab可有效抑制携带致癌NRG1融合基因的患者来源和同源细胞系以及异种移植模型的生长

Odintsov, Igor; Lui, Allan J W; Sisso, Whitney J; Gladstone, Eric; Liu, Zebing; Delasos, Lukas; Kurth, Renate I; Sisso, Exequiel M; Vojnic, Morana; Khodos, Inna; Mattar, Marissa S; de Stanchina, Elisa; Leland, Shawn M; Ladanyi, Marc; Somwar, Romel